High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

BACKGROUND: Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) is emergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Ping, Freitag, C. Eric, Wei, Lai, Zhang, Yunxiang, Parwani, Anil V., Li, Zaibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212599/
https://www.ncbi.nlm.nih.gov/pubmed/32393302
http://dx.doi.org/10.1186/s13000-020-00971-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212599/
https://www.ncbi.nlm.nih.gov/pubmed/32393302
http://dx.doi.org/10.1186/s13000-020-00971-7

Ejemplares similares